HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Goes Local With Personal-Care Innovation, Projects H2 Impacts

This article was originally published in The Rose Sheet

Executive Summary

The Anglo-Dutch firm has been slashing costs and establishing teams in local markets to lay the groundwork for R&D and marketing investments that are expected to pay off in the fiscal 2017 second half. During a July 20 call with investors, CEO Paul Polman discussed local innovations that are already making waves.

You may also be interested in...



Unilever Primes Mob Of New Brands To Be ‘Future Fit’ In Hyper-Fragmented World

Unilever’s growth focus will continue to be its core assets, but in a hyper-fragmented global marketplace the firm is escalating new brand creation, with more than a dozen in the pipeline. The firm’s Alan Jope, president of personal care, discusses.

Cosmetics News In Brief: Unilever Moves Into Makeup; L'Oreal Divests The Body Shop; More

"The color cosmetics category has been showing high growth rates, driven by social media content, channel diversity and democratization of professional makeup techniques," Unilever's Personal Care President Alan Jope notes in a June 19 release announcing the acquisition of Hourglass Cosmetics. More news in brief.

Unilever Introduces Baby Dove Line With #RealMoms Conversation

“There’s no such thing as perfect parents, only real ones,” says Dove as it launches its new Baby Dove line and associated promotions challenging parenting stereotypes.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel